The success of the Phase 3 study reverberated beyond the clinic, sending the company’s shares up more than a third in a ...
Cryptopolitan on MSN
This promising anti-aging drugs just failed its human test
One of the most studied lifespan-extending drugs in animals has just failed its test on humans in a 13-week clinical trial co ...
The mRNA-based Covid vaccines helped blunt the impact of the pandemic but also sparked political backlash that has threatened ...
Kelonia is developing a next-gen blood cancer treatment that’ll reprogram T-cells to help patients’ immune systems fight ...
Yesteryear, the buzzy new debut novel by Caro Claire Burke, has the kind of premise it’s hard to look away from: a tradwife ...
From lifestyle habits to emotional support, the absence of marriage or a partner may quietly influence cancer risk in ways we’re only beginning to understand.
GLP-1 generics enter the world’s diabetes capital and are added to bridal packages to cut ‘food noise’; can they fix India's ...
Bicycling on MSN
The real benefit of riding indoors? Better rides outside
It’s not just about chasing watts. A pioneering Zwift coach explains how trainer time helps cyclists clean up their form, ...
AVAI, BIOA, NAGE, LLY, and NVO Lead a New Wave of Metabolic and Molecular Anti-Aging Therapies Issued on behalf of Avaí Bio, Inc. Companies mentioned in this article: Avaí Bio, Inc. (OTCQB: AVAI), ...
Researchers at Oregon Health & Science University have uncovered a key reason why immunotherapy has largely failed in pancreatic cancer—and identified a promising strategy to overcome that resistance.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results